4 results
* Primary objective: To determine the effect of 78-weeks therapy with omalizumab compared to placebo on the number of sub-epithelial eosinophils, a marker of airway inflammation, in patients with persistent moderate to severe allergic asthma. *…
Primary: (part 3) Potential of BPR277 1% ointment b.i.d. to improve the clinical severity of lesional skin in the majority of NS patients at end of treatment versus baseline of >= 2 points, dose range and regimen relationship on clinical…
The first objective to investigate is the pharmacokinetics of DP tobramycin using the Cyclops® at four different dosages. The other objective is the local tolerability of DP tobramycin using the Cyclops® at four different dosages.
The main objectives are to investigate the pharmacokinetic properties of DP tobramycin via the Cyclops® at different dosages in children with CF, together with the local tolerability.